Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023
Regen BioPharma, Inc. cordially welcomes both individual and institutional investors, as well as advisors and analysts, to join us for an engaging and live presentation at the Emerging Growth Conference.
Regen BioPharma, Inc., a biotech firm specializing in various early-stage medical treatments like cell therapies, RNA vaccines, RNA and DNA therapeutics, as well as small molecule drugs, is set to participate in the upcoming Emerging Growth Conference on August 10, 2023. More details about the conference can be found at https://emerginggrowth.com/conference/.
Join us for this exciting, engaging online event where current shareholders and the investment community can directly communicate with Dr. David Koos, the CEO of our company. Take this chance to ask your questions during the event and rest assured that Dr. Koos and his team will endeavor to address as many queries as they can within the time allocated.
According to Dr. David Koos, the Company's Chairman and CEO, we aim to utilize this period to inform our stakeholders about our future funding and program strategies, the current status of our research program, and address any inquiries from our shareholders.
Regen BioPharma, Inc. is scheduled to give a presentation from 11:25 to 11:55 Eastern time on Thursday August 10, 2023. To secure your spot at the conference and stay informed about any new developments, please sign up here: https://goto.webcasts.com/starthere.jsp?ei=1603283&tp_key=7656c5070a&sti=rgbp
If participants are unable to attend the event live on the conference day, a recorded webcast will also be accessible on EmergingGrowth.com.
About the Growing and Developing EventThe Growing and Developing event serves as a productive platform for corporations to showcase and share their fresh offerings, services, and noteworthy updates with investors. This event conveniently allows them to do so from their workplace, saving valuable time.
The blog section of the Conference is dedicated to highlighting various companies that operate in a diverse set of industries experiencing growth. These companies possess capable management teams, offer innovative products and services, and have a strategic focus with effective execution. The blog aims to showcase the immense potential these companies have for long-term growth. It caters to a vast audience consisting of numerous individual and institutional investors, along with investment advisors and analysts.
Information about Regen BioPharma Inc.: Regen BioPharma, Inc. is a biotechnology company that is listed on the stock market under the symbols PINK: RGBP and PINK: RGBPP. The company is dedicated to the field of immunology and immunotherapy. It aims to develop and test innovative technologies quickly, starting from pre-clinical studies and advancing to Phase I/II clinical trials. Presently, the company focuses on using mRNA and small molecules to create therapies for cancer and autoimmune diseases. To find out more about Regen BioPharma, you can visit their website at http://www.regenbiopharmainc.com.
Please note: The following news update might include statements regarding future events. It is important to acknowledge that these statements are inherently exposed to potential risks and uncertainties, some of which cannot be accurately anticipated or measured. As a result, the actual outcome of future events may significantly differ from what is described or suggested within these forward-looking statements. Some of the risks and uncertainties that can impact forward-looking statements encompass government regulations, competition, and other substantial risks.
Regen BioPharma Inc., under the leadership of David R. Koos, Ph.D., is headed by a prominent individual who holds the positions of Chairman and Chief Executive Officer. Should you wish to reach out to him, you can contact him at +1-619-722-5505 or send a fax to +1-619-330-2328. Alternatively, you can also drop him an email at [email protected].
Stay connected with us on Twitter to receive the latest news and updates: https://twitter.com/TheRegenBio
Regen BioPharma, Inc. has announced new updates in their latest blog post.
